암 환자의 mutation 중에서 mRNA 백신 표적으로 가장 적합한 변이를 자동 선별합니다.

왜 4-stage 통합?
• NetMHCpan만으로는 부족 — 단백질 표면에 노출된 변이만 면역 인식 가능
• AlphaFold만으로도 부족 — 면역 binding affinity 계산 안 됨
• Bio-LLM으로 문헌 검증 추가 — 임상시험 검증된 변이 우선

Combined Score 가중치:
AlphaFold (RSA × pLDDT) 30%
Protenix (antibody-antigen) 25%
NetMHCpan (MHC binding) 30%
Bio-LLM (문헌 검증) 15%

Tier 분류:
Tier 1 (≥7) Strong — mRNA 백신 즉시 후보
Tier 2 (≥5) Moderate — H3K27M 같은 검증된 변이
Tier 3 (≥3) Weak — 추가 검증 필요
Tier 4 (<3) Reject — 내부 위치 또는 binding 약함

💡 시뮬 실행: 아래 4개 시나리오 중 하나 선택 → 결과 즉시 표시
Stage 1: AlphaFold?
3D 구조 + RSA (Relative Solvent Accessibility)? + pLDDT? (30%)
Stage 2: Protenix? v2
antigen?-antibody binding (25%)
Stage 3: NetMHCpan?
MHC? IC50? + %rank (30%)
Stage 4: Bio-LLM
PubMed + trial 검증 (15%)

새 시뮬레이션 실행

시뮬레이션 결과 ranking

데모 8세 소아 GBM (NeoVax 민서 케이스)

HLA: A*02:01,A*24:02,B*44:03,B*51:01
5.64
/ 10
Tier 2 (Moderate candidate) Top 1 Neoantigen (신생항원)?: H3-3A K28M
전체 ranking 보기 (8개)
# Gene Mut HLA AF PN NM BL Total Tier
1 H3-3A K28M A*02:01 3.2 3.6 10.0 5.2 5.64 Tier 2 (Moderate candidate)
2 H3-3A K28M B*44:03 3.2 3.6 3.0 5.2 3.54 Tier 3 (Weak candidate)
3 ATRX P1402S B*44:03 1.6 1.2 3.0 0.0 1.66 Tier 4 (Reject)
4 TP53 R175H A*02:01 0.5 1.1 0.0 4.7 1.11 Tier 4 (Reject)
5 TP53 R175H B*44:03 0.5 1.1 0.0 4.7 1.11 Tier 4 (Reject)
6 ATRX P1402S A*02:01 1.6 1.2 0.0 0.0 0.76 Tier 4 (Reject)
7 PTEN R130G A*02:01 0.2 1.0 0.0 1.8 0.59 Tier 4 (Reject)
8 PTEN R130G B*44:03 0.2 1.0 0.0 1.8 0.59 Tier 4 (Reject)

데모 폐선암 환자

HLA: A*33:03,A*33:03,B*46:01,B*44:03
4.33
/ 10
Tier 3 (Weak candidate) Top 1 Neoantigen (신생항원)?: EGFR L858R
전체 ranking 보기 (8개)
# Gene Mut HLA AF PN NM BL Total Tier
1 EGFR L858R A*33:03 1.1 1.1 10.0 4.8 4.33 Tier 3 (Weak candidate)
2 EGFR L858R B*46:01 1.1 1.1 7.0 4.8 3.43 Tier 3 (Weak candidate)
3 EGFR T790M A*33:03 0.9 1.1 7.0 4.5 3.31 Tier 3 (Weak candidate)
4 EGFR T790M B*46:01 0.9 1.1 7.0 4.5 3.31 Tier 3 (Weak candidate)
5 TP53 R175H A*33:03 0.5 1.1 3.0 4.7 2.01 Tier 4 (Reject)
6 KRAS G12C A*33:03 1.3 1.1 0.0 6.0 1.58 Tier 4 (Reject)
7 KRAS G12C B*46:01 1.3 1.1 0.0 6.0 1.58 Tier 4 (Reject)
8 TP53 R175H B*46:01 0.5 1.1 0.0 4.7 1.11 Tier 4 (Reject)

데모 흑색종 환자

HLA: A*24:02,A*02:01,B*46:01,B*46:01
2.45
/ 10
Tier 4 (Reject) Top 1 Neoantigen (신생항원)?: NRAS Q61R
전체 ranking 보기 (10개)
# Gene Mut HLA AF PN NM BL Total Tier
1 NRAS Q61R A*24:02 2.0 1.2 3.0 4.4 2.45 Tier 4 (Reject)
2 NRAS Q61R B*46:01 2.0 1.2 3.0 4.4 2.45 Tier 4 (Reject)
3 BRAF V600E A*24:02 1.0 1.1 0.0 6.9 1.61 Tier 4 (Reject)
4 BRAF V600E B*46:01 1.0 1.1 0.0 6.9 1.61 Tier 4 (Reject)
5 PTEN R130G A*24:02 0.2 1.0 3.0 1.8 1.49 Tier 4 (Reject)
6 TP53 R175H A*24:02 0.5 1.1 0.0 4.7 1.11 Tier 4 (Reject)
7 TP53 R175H B*46:01 0.5 1.1 0.0 4.7 1.11 Tier 4 (Reject)
8 PTEN R130G B*46:01 0.2 1.0 0.0 1.8 0.59 Tier 4 (Reject)
9 CDKN2A R80* A*24:02 0.6 1.1 0.0 0.0 0.43 Tier 4 (Reject)
10 CDKN2A R80* B*46:01 0.6 1.1 0.0 0.0 0.43 Tier 4 (Reject)

데모 췌장암 환자

HLA: A*24:02,A*24:02,B*51:01,B*51:01
1.60
/ 10
Tier 4 (Reject) Top 1 Neoantigen (신생항원)?: SMAD4 R361C
전체 ranking 보기 (8개)
# Gene Mut HLA AF PN NM BL Total Tier
1 SMAD4 R361C B*51:01 1.4 1.1 3.0 0.0 1.60 Tier 4 (Reject)
2 KRAS G12D A*24:02 1.3 1.1 0.0 5.8 1.55 Tier 4 (Reject)
3 KRAS G12D B*51:01 1.3 1.1 0.0 5.8 1.55 Tier 4 (Reject)
4 TP53 R175H A*24:02 0.5 1.1 0.0 4.7 1.11 Tier 4 (Reject)
5 TP53 R175H B*51:01 0.5 1.1 0.0 4.7 1.11 Tier 4 (Reject)
6 SMAD4 R361C A*24:02 1.4 1.1 0.0 0.0 0.70 Tier 4 (Reject)
7 CDKN2A R80* A*24:02 0.6 1.1 0.0 0.0 0.43 Tier 4 (Reject)
8 CDKN2A R80* B*51:01 0.6 1.1 0.0 0.0 0.43 Tier 4 (Reject)